Photocure ASA - Annual General Meeting
The Annual General Meeting in Photocure ASA took place on 25 April 2007. The General Meeting approved the Directors' Report and the Annual Accounts, as well as the Board of Directors' proposed distribution of for 2006.
Erik Engebretsen, Jon Hindar, Lars Lindegren and Birgit Stattin Norinder were re-elected for as a members of the Board of Directors. In addition, Kari E. Krogstad was elected as a new director of the Board. All were elected for a period of one year. The new Board of Directors of Photocure ASA consists of:
Erik Engebretsen, Chairman of the Board
Jon Hindar, Board member
Kari E. Krogstad, Board member
Lars Lindegren, Board member
Birgit Stattin Norinder, Board member
The Nomination Committee was elected for a period of one year. The Nomination Committee consists of:
Jónas Einarsson
Tharald Brøvig
Jon Ringvold
In accordance with the proposals of the Board of Directors, the General Meeting also resolved to grant authority to the Board to increase the share capital and to change the articles of association.
For further information, please contact:
President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
www.photocure.com
Photocure ASA is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of different types of cancer.
Photocure has three products on the market: Metvix® cream combined with the Aktilite® lamp for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix® for the diagnosis of bladder cancer. In addition, the company has several follow-on products and technologies in the pipeline.